Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

Nov 17, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Myriam JeanAbderrazzak Merzouki

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Jun 24, 2010·Regulatory Peptides·Ulrich WernerWerner Kramer

The contribution of incretin hormones to the pathogenesis of type 2 diabetes

Sep 15, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Juris J Meier

Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells

Oct 31, 2015·Diabetes Research and Clinical Practice·Petra AugsteinLeonard C Harrison

Update on incretin hormones

May 2, 2012·Annals of the New York Academy of Sciences·Liza K Phillips, Johannes B Prins

Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index

Mar 18, 2013·Journal of Diabetes Investigation·Qianlin WuHaoming Tian

Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis

Apr 5, 2016·Journal of Diabetes Investigation·Marco Calogero AmatoCarla Giordano

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

Jan 14, 2011·The American Journal of Medicine·Michael A Nauck

Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine

Jun 4, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Hsin-Chieh Tang, Calvin Yu-Chian Chen

Effects of diet soda on gut hormones in youths with diabetes.

Mar 14, 2012·Diabetes Care·Rebecca J BrownKristina I Rother

GIP: an inconsequential incretin or not?

Jul 1, 2010·Diabetes Care·Richard E Pratley

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Apr 30, 2010·Diabetes·Juris J Meier, Michael A Nauck

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes

Mar 11, 2010·Diabetes·Marzieh SalehiDavid A D'Alessio

Effective gene delivery of shBMP-9 using polyethyleneimine-based core-shell nanoparticles in an animal model of insulin resistance

Jan 16, 2019·Nanoscale·Yanjun JiaGangyi Yang

Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease

Apr 3, 2015·Physiological Reviews·Darleen A Sandoval, David A D'Alessio

Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the China National Diabetes and Metabolic Disorders Study

Jul 17, 2014·The Journal of Clinical Endocrinology and Metabolism·Tianpeng ZhengHaoming Tian

Pharmacotherapy of hyperglycemia

Sep 12, 2009·Expert Opinion on Pharmacotherapy·Kristen M Kulasa, Robert R Henry

The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Mar 17, 2016·American Journal of Physiology. Endocrinology and Metabolism·Benedikt A AulingerDeborah A Elder

Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants

Oct 1, 2011·Clinical Drug Investigation·Jens Juul Holst, Maria A McGill

Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

Apr 29, 2010·American Journal of Physiology. Endocrinology and Metabolism·Filip K Knop

No change in serum incretins levels but rise of leptin levels after smoking cessation: a pilot study

Mar 19, 2016·Physiological Research·A PankovaM Haluzik

Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants

Jan 1, 2012·Clinical Drug Investigation·Jens Juul Holst, Maria A McGill

Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity.

Jul 3, 2021·International Journal of Molecular Sciences·Tohru HiraHiroshi Hara

❮ Previous

Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

Abstract

Associated Clinical Trials

Short-term Effect of Intensive Insulin Therapy on Incretin Secretion

References

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

Heritability of proliferative diabetic retinopathy.

Congenital rubella: citation virus or viral cause of type 1 diabetes?

Citations

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

The contribution of enteroinsular hormones to the pathogenesis of type 2 diabetes mellitus.

An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Glucagon regulates hepatic kisspeptin to impair insulin secretion

New incretin hormonal therapies in humans relevant to diabetic cats

Targeting the glucagon receptor family for diabetes and obesity therapy

Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

The contribution of incretin hormones to the pathogenesis of type 2 diabetes

Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells

Update on incretin hormones

Changes of blood glucose and gastrointestinal hormones 4 months after Roux-en-Y gastric bypass surgery in Chinese obese type 2 diabetes patients with lower body mass index

Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

Design of glucagon-like Peptide-1 receptor agonist for diabetes mellitus from traditional chinese medicine

Effects of diet soda on gut hormones in youths with diabetes.

GIP: an inconsequential incretin or not?

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes

Effective gene delivery of shBMP-9 using polyethyleneimine-based core-shell nanoparticles in an animal model of insulin resistance

Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease

Increased plasma DPP4 activity is predictive of prediabetes and type 2 diabetes onset in Chinese over a four-year period: result from the China National Diabetes and Metabolic Disorders Study

Pharmacotherapy of hyperglycemia

The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?

Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants

Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?

No change in serum incretins levels but rise of leptin levels after smoking cessation: a pilot study

Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants

Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity.

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Related Papers

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

The physiology of glucagon-like peptide 1

The role of incretins in glucose homeostasis and diabetes treatment.

Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?